Feb 06, 2025 8:49pm EST RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
Jan 27, 2025 8:00am EST RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
Jan 08, 2025 8:00am EST RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
